Loading publications…
The last 5 uploaded publications
Prognostic value of PSMA PET against CHAARTED criteria in an ENZAMET sub-cohort.
Zahra Sabahi, Nathan Papa, Wolfgang P. Fendler, Andrew Nguyen, Keith Wong, Narjess Ayati, Bao Ho, Jeffrey Chen, Thomas W. Cusick, Irene A. Burger, Megan Crumbaker, Gavin Marx, Shikha Sharma, Mark Frydenberg, Shahneen Sandhu, Ian D. Davis, Martin R. Stockler, Christopher J. Sweeney, Anthony M. Joshua, Louise Emmett (2025). Prognostic value of PSMA PET against CHAARTED criteria in an ENZAMET sub-cohort.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.5091.
Article62 days agoCAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study
Adrian Minson, Nada Hamad, Chan Y. Cheah, Constantine S. Tam, Piers Blombery, David Westerman, David Ritchie, Huw Morgan, Nicholas Holzwart, Stephen Lade, Mary Ann Anderson, Amit Khot, John F. Seymour, Molly Robertson, Imogen Caldwell, Georgina L. Ryland, Javad Saghebi, Zahra Sabahi, Jing Xie, Rachel Koldej, Michael Dickinson (2023). CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study. , 143(8), DOI: https://doi.org/10.1182/blood.2023021306.
Article62 days ago